CGTLive’s Weekly Rewind – April 14, 2023

Review top news and interview highlights from the week ending April 14, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Achieving Regeneration in Lumbar Degenerative Disc Disease

Matthew Gornet, MD, spine surgeon from The Orthopedic Center of St. Louis discussed data seen with IDCT cell therapy.

2. Stephan Züchner, MD, PhD, on Gene-Targeted Approaches to Neuromuscular Disease

The professor for human genetics and neurology at the University of Miami Miller School of Medicine discussed past, current, and future approaches to diagnosing and treating neuromuscular diseases.

3. Cell Therapy Combination Shows Antitumor Response in Ewing Sarcoma

Vigil cell therapy previously showed some efficacy as a monotherapy in patients with ovarian cancer.

4. Bhagirathbhai Dholaria, MBBS, on Progress With CAR T in Blood Cancers and Addressing Relapses

The assistant professor of medicine at Vanderbilt University Medical Center discussed the work that has been done in the field in the past 10 years and work that still remains to be done.

5. Freeline Goes All in on Gaucher Disease

The company’s pipeline is down to 1 remaining clinical-stage program that is enrolling in its first-in-human trial.

Related Videos
Binod Dhakal, MD, on Assessing Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
Brian Van Tine, MD, PhD, on Further Research With Cell Therapy in Synovial Sarcoma
Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma
Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic Controllers
Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity
John Leonard, PhD, on an AAV Approach to Exon 51 Skipping in DMD
Joseph Fraietta, PhD, on Investigating Molecular Pathways of CAR T-Cell Resistance
Related Content
© 2023 MJH Life Sciences

All rights reserved.